 Clene Nanomedicine

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Clene Inc. (CLNN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Clene Inc. (CLNN) Have the Potential to Rally 238% as Wall Street Analysts Expect?

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics, today announced the completion of enrollment in the HEALEY ALS Platform Trial, led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. Clene's lead drug candidate, CNM-Au8®, a gold nanocrystal suspension, which has received U.S. Food and Drug Administration (FDA) Orphan Drug designation for the treatment of amyotrophic lateral sclerosis (ALS), is one of several drugs being evaluated in this innovative platform trial.

Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial

SALT LAKE CITY, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with its potential first-in-class catalytically active nanocrystal suspension, today reported its third quarter 2021 operating and financial results.

Clene Reports Third Quarter 2021 Operating and Financial Highlights

SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the launch of a second U.S. Food and Drug Administration (FDA) expanded access program (CNMAu8.EAP02) with CNM-Au8 for people living with amyotrophic lateral sclerosis (ALS).

Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis

CNM-Au8® , a catalytically active gold nanocrystal suspension, significantly improved brain energetic metabolism in Parkinson's patients CNM-Au8® , a catalytically active gold nanocrystal suspension, significantly improved brain energetic metabolism in Parkinson's patients

Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021

SALT LAKE CITY, Sept. 09, 2021 (GLOBE NEWSWIRE) --  Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the final patient visit has been completed in its Phase 2 RESCUE-ALS study and that trial close-out activities have begun. RESCUE-ALS investigated the efficacy, safety, pharmacokinetics and pharmacodynamics of Clene's lead drug candidate, CNM-Au8®, a catalytically-active gold nanocrystal suspension, in patients with early amyotrophic lateral sclerosis (ALS). The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.

Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021

SALT LAKE CITY, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that the Company will present at the following investor conferences in September:

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension

Clene Reports Second Quarter 2021 Operating and Financial Highlights

Clene Inc (NASDAQ: CLNN) has shared positive top-line results from the Phase 2 REPAIR trials investigating the improvement of brain energetic metabolism in Parkinson's disease (PD) and multiple sclerosis (MS). The objective of the REPAIR program was to demonstrate the effects of Clene's nanotherapeutic, CNM-Au8, on brain energy metabolites in two studies of patients with Parkinson's disease (REPAIR-PD) and multiple sclerosis (REPAIR-MS).

Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's, Multiple Sclerosis

The stock price of Clene Inc. (NASDAQ: CLNN) increased by over 7% pre-market. This is why it happened.

CLNN Stock Price Increases Over 7% Pre-Market: Why It Happened

Achieved a statistically significant increase in the Phase 2 program's primary endpoint  (mean change in brain NAD+/NADH ratio)

Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson's Disease and Multiple Sclerosis

Clene is a developer of proprietary, patented, nanocatalysis therapy for neurodegenerative diseases. They have ongoing phase 2 trials in multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis.

Clene: Nanomedicines For Neurodegenerative Diseases

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that its management team will be presenting at Canaccord Genuity's 41st Annual Growth Conference.

Clene to Present at Canaccord Genuity's Annual Growth Conference

Blink Charging

Creatd Inc

Arcimoto

Canoo

Marin Software

Workhorse Group

If you're thinking about going for the ultimate contrarian trade, here is a list of the most heavily shorted stocks. The post 7 Highly Shorted Stocks Heading Into Q3 2021 appeared first on InvestorPlace.

7 Highly Shorted Stocks Heading Into Q3 2021

Carver Bancorp

GoodRx Holdings

iRobot

Tanger Factory Outlet Centers

Sequential Brands Group

Upstart Holdings

These shares are among the stocks with the most short sell positions The post 7 Short-Squeeze Stocks To Buy In July For Contrarian Investors appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.

7 Short-Squeeze Stocks To Buy In July For Contrarian Investors

SALT LAKE CITY, June 28, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced that it has been added as a member of the U.S. small-cap Russell 2000® Index and the all-cap Russell 3000® Index, effective after the U.S. market opens today, June 28, 2021, as part of the 2021 Russell indexes reconstitution.

Clene Added to Membership of Russell 2000® Index

International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer's disease

Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging

Preliminary blinded efficacy data suggest CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients

Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 Annual Meeting

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients

Clene Reports First Quarter 2021 Operating and Financial Highlights

IP portfolio now totals over 160 patents issued, allowed, and pending IP portfolio now totals over 160 patents issued, allowed, and pending

Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Technology

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics

Clene Reports Full Year 2020 Operating and Financial Highlights

SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on the treatment of neurodegenerative disease using nanocatalysis, today has featured its publicly filed business overview and corporate presentation on M-Vest.com and announced upcoming presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference hosted by M Vest LLC.

Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference and Launch of Clene Spotlight Webpage on M Vest LLC

World's first ALS platform trial led by Mass General Hospital and conducted at NEALS centers throughout the United States is a registration trial World's first ALS platform trial led by Mass General Hospital and conducted at NEALS centers throughout the United States is a registration trial

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 study evaluating the efficacy and safety of lead drug candidate, CNM-Au8, in multiple sclerosis. The analyses compare changes in functional composite scores over the study treatment period to the baseline.

Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies

SALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, will present blinded interim data from its VISIONARY-MS study and updated interim data from its REPAIR-MS study in on-demand presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) ACTRIMS Forum 2021 taking place virtually from February 25-27, 2021. Together, these complementary Phase 2 studies evaluate the efficacy, safety, and central nervous system (CNS) metabolic effects of Clene's lead drug candidate CNM-Au8, a bioenergetic nanocatalyst, in multiple sclerosis (MS) patients.

News for Clene Nanomedicine Stock (CLNN)